A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients

Potchavit Aphinives, Damnern Vachirodom, Chaiyut Thanapaisal, Dhanes Rangsrikajee, Ongart SomintaraDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandBackground: We previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aphinives P, Vachirodom D, Thanapaisal C, Rangsrikajee D, Somintara O
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f3af229ddbc44db2b571c9dec9745bff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3af229ddbc44db2b571c9dec9745bff
record_format	dspace
spelling	oai:doaj.org-article:f3af229ddbc44db2b571c9dec9745bff2021-12-02T02:46:41ZA comparison of letrozole and anastrozole followed by letrozole in breast cancer patients1179-1314https://doaj.org/article/f3af229ddbc44db2b571c9dec9745bff2015-01-01T00:00:00Zhttp://www.dovepress.com/a-comparison-of-letrozole-and-anastrozole-followed-by-letrozole-in-bre-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314 Potchavit Aphinives, Damnern Vachirodom, Chaiyut Thanapaisal, Dhanes Rangsrikajee, Ongart SomintaraDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandBackground: We previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ) due to reimbursement policy. We found that patients with A-LTZ had better overall survival (OS) than did patients with ANZ alone. This study aimed to prove that patients with A-LTZ also had better OS than patients with letrozole (LTZ) alone.Methods: All medical records of the breast cancer patients taking LTZ with or without ANZ between 2004 and 2013 were reviewed. All patients were divided into two groups: the LTZ group included patients treated with LTZ alone, and the A-LTZ group included patients treated with ANZ who were automatically changed to LTZ due to change of the reimbursement policy.Results: From 359 cases, there were 179 cases in the LTZ group and 180 cases in the A-LTZ group. The mean age of patients in the LTZ group was 53.7 years and in the A-LTZ group was 54.2 years. The distribution of clinical stages among the LTZ group versus the A-LTZ group was 21 versus 4 (stage 1), 86 versus 116 (stage 2), 55 versus 46 (stage 3), and 17 versus 14 (stage 4), respectively. Among the LTZ patients, 63.7% took aromatase inhibitor monotherapy and 36.3% had a switching strategy, while in the A-LTZ group, 53.9% took AI monotherapy and 46.1% had a switching strategy. OS of the A-LTZ group was longer than that of the LTZ group.Conclusion: The patients in A-LTZ, taking ANZ followed by LTZ had better OS than those in LTZ, taking LTZ alone.Keywords: estrogen receptor-positive, hormonal responsive, tamoxifenAphinives PVachirodom DThanapaisal CRangsrikajee DSomintara ODove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 37-41 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Aphinives P Vachirodom D Thanapaisal C Rangsrikajee D Somintara O A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
description	Potchavit Aphinives, Damnern Vachirodom, Chaiyut Thanapaisal, Dhanes Rangsrikajee, Ongart SomintaraDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandBackground: We previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ) due to reimbursement policy. We found that patients with A-LTZ had better overall survival (OS) than did patients with ANZ alone. This study aimed to prove that patients with A-LTZ also had better OS than patients with letrozole (LTZ) alone.Methods: All medical records of the breast cancer patients taking LTZ with or without ANZ between 2004 and 2013 were reviewed. All patients were divided into two groups: the LTZ group included patients treated with LTZ alone, and the A-LTZ group included patients treated with ANZ who were automatically changed to LTZ due to change of the reimbursement policy.Results: From 359 cases, there were 179 cases in the LTZ group and 180 cases in the A-LTZ group. The mean age of patients in the LTZ group was 53.7 years and in the A-LTZ group was 54.2 years. The distribution of clinical stages among the LTZ group versus the A-LTZ group was 21 versus 4 (stage 1), 86 versus 116 (stage 2), 55 versus 46 (stage 3), and 17 versus 14 (stage 4), respectively. Among the LTZ patients, 63.7% took aromatase inhibitor monotherapy and 36.3% had a switching strategy, while in the A-LTZ group, 53.9% took AI monotherapy and 46.1% had a switching strategy. OS of the A-LTZ group was longer than that of the LTZ group.Conclusion: The patients in A-LTZ, taking ANZ followed by LTZ had better OS than those in LTZ, taking LTZ alone.Keywords: estrogen receptor-positive, hormonal responsive, tamoxifen
format	article
author	Aphinives P Vachirodom D Thanapaisal C Rangsrikajee D Somintara O
author_facet	Aphinives P Vachirodom D Thanapaisal C Rangsrikajee D Somintara O
author_sort	Aphinives P
title	A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
title_short	A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
title_full	A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
title_fullStr	A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
title_full_unstemmed	A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
title_sort	comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/f3af229ddbc44db2b571c9dec9745bff
work_keys_str_mv	AT aphinivesp acomparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT vachirodomd acomparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT thanapaisalc acomparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT rangsrikajeed acomparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT somintarao acomparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT aphinivesp comparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT vachirodomd comparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT thanapaisalc comparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT rangsrikajeed comparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients AT somintarao comparisonofletrozoleandanastrozolefollowedbyletrozoleinbreastcancerpatients
_version_	1718402199125491712

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients

Ejemplares similares